InformAI Receives Supplemental CPRIT Grant for Product Commercialization

InformAI is pleased to announce that we are the recipient of a supplemental product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) for $465,188 to support product development and market commercialization of our RadOncAI: AI guided dose prediction platform for radiation oncology. RadOncAI streamlines radiation treatment, speeding up the head & neck radiation therapy dose planning process while minimizing radiation exposure to healthy tissues. InformAI received one of eight supplemental awards to Texas-based companies pursuing innovative cancer treatments or technologies.

About InformAI

InformAI is a technology company dedicated to advancing healthcare through AI-enabled clinical solutions. We specialize in creating sophisticated products for oncology and diagnostic imaging to improve patient outcomes. Leveraging strong partnerships, we deliver impactful solutions in large and fast-growing markets.

About CPRIT

CPRIT was created by the Texas Legislature and approved by a statewide vote in 2007 to lead the Lone Star State’s fight against cancer. In 2019, Texas voters again voted overwhelmingly to continue CPRIT with an additional $3 billion for a total $6 billion investment in cancer research and prevention. To date, the agency has awarded more than $3.9 billion in grants to Texas research institutions and organizations through its academic research, prevention, and product development research programs. CPRIT has also recruited 334 distinguished researchers to Texas, funded the establishment, expansion, or relocation of 74 companies to Texas, and supported 10.5 million prevention services reaching all 254 counties in Texas. Learn more at https://cprit.texas.gov.